CHRS Coherus Oncology, Inc.
Healthcare$1.64+1.86%ClosedMarket Cap: $200.8M
As of 2026-05-26
Valuation
P/E (TTM)
1.17
PEG
0.00
P/B
2.79
P/S
4.20
EV/EBITDA
-0.82
DCF Value
$-0.26
FCF Yield
-86.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.0%
Operating Margin
-362.1%
Net Margin
-323.5%
ROE
-174.7%
ROA
-57.0%
ROIC
-125.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $12.3M | 61.9% | $-36.2M | $-37.9M | $— | — |
| Q4 null | $12.7M | 61.2% | $-45.9M | $-37.3M | $— | — |
| FY null | $42.2M | 57.9% | $-179.5M | $-170.3M | $— | — |
| Q3 null | $11.6M | 59.5% | $-42.2M | $-35.1M | $— | — |
| Q2 null | $10.3M | 57.0% | $-45.5M | $-41.3M | $— | — |
| Q1 null | $7.6M | 51.3% | $-45.4M | $-56.6M | $— | — |
| Q4 null | $54.1M | 37.5% | $-42.2M | $-50.7M | $— | — |
| FY null | $267.0M | 56.0% | $-111.7M | $28.5M | $— | — |
| Q3 null | $70.8M | 70.7% | $-6.4M | $-10.8M | $— | — |
| Q2 null | $65.0M | 54.5% | $-20.5M | $-12.9M | $— | — |
| Q1 null | $2.3M | 37.7% | $-67.8M | $102.9M | $— | — |
| Q4 2023 | $91.5M | 7.6% | $-68.9M | $-79.7M | $-0.71 | — |